TLDR
- Shares of Olema Pharmaceuticals (OLMA) surged 8.5% Monday following a fourth-quarter earnings per share that narrowly topped analyst forecasts, posting a $0.50 loss versus the anticipated $0.51.
- Olema disclosed a GAAP net loss totaling $46.1 million in Q4 2025 and $162.5 million across the entire fiscal year.
- Following the quarterly report, Stifel maintained its Buy recommendation with a $48 price objective, highlighting cash reserves extending through mid-2028.
- A recent setback in Roche’s persevERA clinical study, which failed its primary endpoint this month, has sparked concerns about Olema’s OPERA-02 trial trajectory.
- Wall Street consensus stands at “Moderate Buy” with a mean price objective of $41, while shares have declined 41% year-to-date despite posting a remarkable 234% advance over the trailing twelve months.
Shares of Olema Pharmaceuticals (OLMA) advanced 8.5% during Monday’s trading session after delivering fourth-quarter financial results that slightly exceeded analyst projections. The biotech stock reached an intraday peak of $16.07 before closing near $15.96, representing a gain from the previous close of $14.71.
Olema Pharmaceuticals, Inc., OLMA
The biotechnology firm disclosed a quarterly loss of $0.50 per share for the fourth quarter of 2025, narrowly surpassing the Street consensus of ($0.51) by one cent. While the margin was slim, it proved sufficient to drive shares higher.
Across fiscal 2025, Olema recorded a GAAP net loss totaling $162.5 million. The fourth quarter alone accounted for $46.1 million of that deficit. Management did not host an earnings conference call following the release.
Despite ongoing losses, the stock has experienced significant volatility. OLMA shares have skyrocketed 234% over the past year, yet have declined 41% year-to-date prior to Monday’s rally.
Monday’s trading volume registered at 518,220 shares — notably below the typical daily average of approximately 1.6 million. The reduced activity may suggest investor hesitation rather than strong conviction behind the upward movement.
Analyst Reaction
Stifel responded promptly to the earnings release, reaffirming its Buy recommendation along with a $48 price objective. The investment firm highlighted Olema’s financial runway extending into mid-2028 as a significant strength, providing adequate resources to reach several critical milestones ahead of palazestrant’s anticipated commercial debut.
Palazestrant is under development as a treatment for second- and third-line metastatic breast cancer, with commercialization targeted for 2027.
The broader analyst community maintains a generally optimistic stance. Ten Wall Street analysts currently hold Buy ratings on the shares, while one maintains a Hold recommendation and another rates it a Sell. The consensus price target stands at $41.00 — representing substantial upside from current trading levels.
Oppenheimer reaffirmed its Outperform rating on March 9th. JPMorgan upgraded its price target from $29 to $32 last November while maintaining an Overweight rating. TD Cowen also holds a Buy stance, contending that palazestrant offers superior characteristics compared to rival therapies.
H.C. Wainwright reduced its price objective to $38 but maintained its Buy rating following recent clinical trial developments.
The Roche Factor
Earlier in March, Roche disclosed that its persevERA clinical trial — assessing giredestrant in combination with palbociclib for first-line metastatic breast cancer — did not achieve statistical significance for its progression-free survival primary endpoint. While a favorable numerical trend was observed, the failure to reach significance carries implications.
The persevERA outcome is broadly interpreted as potentially predictive for Olema’s Phase 3 OPERA-02 study, which is evaluating palazestrant. Top-line results from OPERA-02 aren’t anticipated before 2028.
Stifel noted that comprehensive persevERA data will likely be unveiled at the ASCO 2026 conference, which could represent the next significant catalyst — or potential challenge — for OLMA shares.
Regarding financial position, Olema maintains a stronger cash position than debt obligations, with a current ratio of 8.03. The stock’s 50-day moving average rests at $24.18, considerably above Monday’s trading range.
Institutional ownership accounts for 91.78% of outstanding shares. Meanwhile, company insiders have been net sellers — disposing of approximately 805,501 shares valued at roughly $23 million during the past quarter.
The company currently carries a market capitalization of approximately $1.09 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
